You are currently viewing Betalin Therapeutics chosen as 1 of top 5 Top Stem Cell Startups in the World!

After Startup Insights, a worldwide operating data science company headquartered in Austria, analyzed 120 stem cell startups from around the world impacting the healthcare sector, Betalin Therapeutics was chosen this year as one of their top 5 choices in the field of stem cell therapies. Startup Insights carries out regular surveys to identify the leaders in research, technology as well as top startups in different fields.

Startup Insights surveyed innovation in the field of healthcare and identified 120 relevant solutions in Stem Cell R&D.  These companies were chosen based on a data-driven startup scouting approach, considering factors such as location, founding year, and technology, among others.

According to Startup Insights, the ability of stem cells to self-renew and also differentiate into specialized cells garners immense therapeutic interest in them. Cell therapy-based solutions seek to replenish stem cells in patients’ bodies and also reverse the disease state. For instance, startups are exploring the use of functional pancreatic cells as a treatment for Type 1 diabetes, one of the leading causes of death worldwide.

Betalin Therapeutics is an Israeli startup that develops a cell-based therapy for insulin-dependent diabetes. Its Engineered Micro Pancreas (EMP) technology allows for the implantation of pancreatic stem cells, which then differentiate into insulin-producing islet cells and restore the body’s ability to produce insulin. The solution uses a unique micro-organ scaffold that mimics the environment of the extracellular matrix (ECM).

About Betalin Therapeutics

Betalin Therapeutics seeks to eliminate the need for insulin injections and glucose testing in diabetes patients with its proprietary transplanted Engineered Micro Pancreas (EMP). The EMP aims to restore normal blood glucose levels by mimicking the function of the pancreas using islet cells encapsulated within a micro-organ matrix scaffold.
The EMP technology helps create connective tissue that enables the body’s beta cells to function properly and produce adequate and functional insulin.

Betalin Therapeutics licensed the novel Engineered Micro Pancreas (EMP) technology developed at The Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.

Contact: Betalin Therapeutics Tel: +972 (52) 296 3130

Source: Startup Insights